Regeneron Pharmaceuticals, Inc. (REGN)
$753.12-1.27%Close
SELLBEAR · day 24
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV8.4%–80.8%
- Market cap
- $77.6B
- Beta
- 0.24
- Div yield
- 0.49%
- P/E (TTM)
- 17.98
- IV-%ile
- 61
- IV ATM
- 35.1%
- Short % float
- 2.13%
- Days to cover
- 2.5
- SI change
- -14.9%
- 1W
- +1.95%
- 1M
- -5.12%
- vs SPY 1W
- +2.09%
- vs SPY 1M
- -7.62%
Industry peers
FMP comparable companies · ranked by market cap
- NVSBUYNovartis AG$273.2BRECOVERYQ 20$143.75-0.99%
- AZNSELLAstraZeneca PLC$246.9BRECOVERYQ 20$159.20-1.59%
- AMGNBUYAmgen Inc.$223.9BRECOVERYQ 22$414.87-1.13%
- GILDSELLGilead Sciences, Inc.$187.4BBULLQ 25$151.17-1.67%
- BIIBBUYBiogen Inc.$33.3BBULLQ 19$225.71-0.22%
- GMABBUYGenmab A/S$22.8BBULLQ 21$37.07-2.14%
- IVBXFInnovent Biologics, Inc.$21.1B$12.14
- REGMFRemeGen Co., Ltd.$5.6B$9.96
- OCULSELLOcular Therapeutix, Inc.$1.7BCRISISQ 3$7.54-4.23%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on REGN?
- LOPJLB’s latest quantitative signal on Regeneron Pharmaceuticals, Inc. (REGN) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is REGN in?
- Regeneron Pharmaceuticals, Inc. (REGN) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Regeneron Pharmaceuticals, Inc. (REGN) do?
- Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neo…